MOUNTAIN VIEW, Calif.,
March 31, 2015 /PRNewswire/
-- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of
medication and supply management solutions for healthcare
institutions, today announced the conclusion of an investigation
into certain whistleblower allegations that had postponed the
filing of its 2014 Annual Report on Form 10-K, and also announced
that the 2014 report has now been filed with the Securities
Exchange Commission. The whistleblower claim was received on
February 27, 2015 and alleged, among
other claims, the existence of a side letter arrangement with a
customer that provided for discounts which were not recorded in the
financial results of the Company.
After a thorough investigation, Omnicell concluded that a letter
was written by a Company sales representative in 2010 to a single
customer that summarized terms of a quotation and was presented to
the customer in the normal course of the sales process. The
Company concluded that the letter did not promise discounts to the
customer that were not included in the Company's financial
statements. Upon review of documents and other information related
to this allegation and other sales activity at the Company, the
Company reaffirmed that financial controls were operating
effectively.
Omnicell takes all allegations of impropriety seriously and
apologizes for any inconvenience caused by the delay of filing its
Annual Report while this matter was investigated.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
OMCL-E
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-inc-announces-conclusion-of-whistleblower-investigation-and-filing-of-2014-annual-report-on-form-10-k-300058100.html
SOURCE Omnicell, Inc.